Linked Life Data

20546499

Source:http://linkedlifedata.com/resource/pubmed/id/20546499

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2011-4-26
pubmed:abstractText
Rapid virological response (RVR) is now considered the strongest predictor of sustained virological response (SVR) in patients with HCV undergoing antiviral treatment, and thus, shorter antiviral treatment for these patients has been suggested. However, no data exist on the predictive value of RVR in HCV carriers with normal ALT values. A total of 137 patients with persistently normal ALT treated with peginterferon alfa 2a and ribavirin were studied. Fifteen patients dropped out early because of side effects, and in 10 patients with HCV-1 treatment was discontinued because of lack of early virological response (EVR). RVR was observed in 68% of the patients (42% patients with HCV-1, 90% HCV-2 and 64% HCV-3). An end-of-treatment response was observed in 86% of the patients (68% HCV-1, 100% HCV-2 and 91% HCV-3). SVR was maintained in 91 patients (46% HCV-1, 97% HCV-2 and 82% HCV-3). Overall, 92% patients with rapid response did obtain HCV eradication vs only 38% of those without rapid response. HCV-1 patients with baseline HCV RNA <400×10(3) IU/mL were more likely to achieve RVR and SVR than those with higher HCV RNA levels. We conclude that patients with genotype 1 and normal ALT who achieve HCV RNA negativity at week 4 may have a higher probability of eradicating their infection. Because of the concomitant favourable demographic and virological features often found in this particular subset of patients, the duration of therapy in these people might be shortened in the case of RVR. Persistently normal alanine aminotransferase levels patients with genotype 2 or 3 have a high chance of achieving SVR, so retesting of HCV RNA during treatment may have no additional practical value in these subjects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1365-2893
pubmed:author
pubmed:copyrightInfo
© 2010 Blackwell Publishing Ltd.
pubmed:issnType
Electronic
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
393-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:20546499-Adult, pubmed-meshheading:20546499-Alanine Transaminase, pubmed-meshheading:20546499-Antiviral Agents, pubmed-meshheading:20546499-Drug Therapy, Combination, pubmed-meshheading:20546499-Female, pubmed-meshheading:20546499-Genotype, pubmed-meshheading:20546499-Hepacivirus, pubmed-meshheading:20546499-Hepatitis C, pubmed-meshheading:20546499-Humans, pubmed-meshheading:20546499-Interferon-alpha, pubmed-meshheading:20546499-Liver, pubmed-meshheading:20546499-Male, pubmed-meshheading:20546499-Middle Aged, pubmed-meshheading:20546499-Polyethylene Glycols, pubmed-meshheading:20546499-RNA, Viral, pubmed-meshheading:20546499-Recombinant Proteins, pubmed-meshheading:20546499-Ribavirin, pubmed-meshheading:20546499-Treatment Outcome, pubmed-meshheading:20546499-Young Adult
pubmed:year
2011
pubmed:articleTitle
Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study.
pubmed:affiliation
Department of Internal Medicine and Liver Unit, Marino Hospital, Rome, Italy. puoti@epatologia.org
pubmed:publicationType
Journal Article, Multicenter Study